๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University454 Ruijin Hospital276 Shanghai Zhongshan Hospital163 RenJi Hospital135 Children's Hospital of Fudan University84
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shanghai

3827 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Effect of the Automatic Surveillance System on Surveillance Rate of Patients with Gastric Premalignant Lesions
NCT06039917Artificial Intelligence, Surveillance
Renmin Hospital of Wuhan University
Not applicable
1,460
Quanzhou, Wuhan, Shanghai
2023-09-10
Recruiting
AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
NCT06035250Gastric Cancer, Image, Pathology
Chinese Academy of Sciences
Observational
200
Beijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai
2023-09-10
Recruiting
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
NCT06056336Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy, Adjuvant Therapy
DrugTislelizumab
Guo Xufeng
Phase 2
73
Shanghai
2023-09-07
Active, closed
A Study of the Safety, Tolerability and Prelinminary Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis
NCT06474416Herpes Simplex Virus Type I Stromal Keratitis
Shanghai BDgene Co., Ltd.
Phase 1
16
Shanghai, Hangzhou, Wenzhou
2023-09-04
Recruiting
Multicenter Clinical Translational Study of "ICU-NO CRBSI" Based on Improvement Science
NCT06085690CRBSI - Catheter Related Bloodstream Infection, Evidence-based Nursing Practice, Central Venous Catheter Related Bloodstream Infection, Central Venous Catheter Associated Bloodstream Infection
Fudan University
Not applicable
8,050
Shanghai
2023-09-04
Active, closed
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
NCT05949619Non-small Cell Lung Cancer
DrugBL-M02D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
14
Shanghai
2023-09-04
Recruiting
CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)
NCT06031727Neovascular Age-related Macular Degeneration(nAMD)
HuidaGene Therapeutics Co., Ltd.
Phase EARLY_PHASE1
12
Shanghai, Tianjin
2023-09-04
Recruiting
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
NCT06002581Parkinson's Disease
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
56
Shanghai
2023-09-03
Not yet open
Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation
NCT06015568Non-Small Cell Lung Cancerใ€EGFR Sensitive Mutation
Betta Pharmaceuticals Co., Ltd.
Phase 1
172
Bengbu, Changsha, Shanghai
2023-09-01
Recruiting
Effectiveness and Health Economics of Endoluminal Treatment of Arteriovenous Graft Fistula.
NCT06470646Hemodialysis Access Failure
RenJi Hospital
Observational
240
Shanghai
2023-09-01
Not yet open
A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT05976568Hepatocellular Carcinoma
DrugsIparomlimab and Tuvonralimab·Sintilimab·Oxaliplatin·Capecitabine
Qilu Pharmaceutical Co., Ltd.
Phase 2/3
668
Nanjing, Shanghai
2023-09-01
Recruiting
Multi-Dimensional MRI Spatial Heterogeneity Analysis for Predicting Key Genes and Prognosis of High-Grade Gliomas: A Multi-Center Study
NCT06002711High-grade Glioma
RenJi Hospital
Observational
500
Shanghai
2023-09-01
Recruiting
A Study for the Disrupted Interpersonal Interaction Among Gaming Disorder Individuals and Treatment
NCT06208358Gaming Disorder
Shanghai Mental Health Center
Not applicable
60
Shanghai
2023-09-01
Recruiting
Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery
NCT06209294Neoadjuvant Immunotherapy, Cervical Cancer, Fertility-sparing Surgery
Xiaohua Wu
Phase 2
30
Shanghai
2023-09-01
Not yet open
Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis
NCT05354674Colorectal Cancer, Liver Metastases
DrugBevacizumab
Fudan University
Observational
302
Shanghai
2023-09-01
Recruiting
Obesity Queue Database
NCT06391320Obesity
RenJi Hospital
Observational
5,000
Shanghai
2023-09-01
Recruiting
Construction of A Multimodal Digital Assessment Model for Myasthenia Gravis
NCT07146425Myasthenia Gravis
Huashan Hospital
Observational
180
Shanghai
2023-08-31
Active, closed
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT06081894Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
DrugAficamten
Cytokinetics
Phase 3
500
Guangzhou, Beijing, Jilin City, Nanjin, Shanghai, Shenyang, Wuhan, Xi'an
2023-08-31
Recruiting
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
DrugOlverembatinib
Ascentage Pharma Group Inc.
Phase 3
350
Bengbu, Chongqing, Guangdong, Zhengzhou, Wuhan, Suzhou, Shanghai, Chengdu
2023-08-31
Recruiting
Surgical Strategy of NSCLC Patients After Neo-adjuvant or Induction Treatment
NCT06534489Non-small Cell Lung Cancer, Surgery
Ruijin Hospital
Observational
50
Shanghai
2023-08-31
Active, closed
Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors
NCT05990452Advanced Solid Tumor
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2
261
Shanghai
2023-08-28
Recruiting
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
NCT06126224Psychosis Associated With Alzheimer's Disease
DrugKarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
500
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Nanchang, Shanghai
2023-08-28
Recruiting
Artificial Intelligence (AI) Analysis of Synchronized Phonocardiography (PCG) and Electrocardiogram(ECG)
NCT06009718Heart Failure
Ruijin Hospital
Observational
3,000
Shanghai
2023-08-25
Recruiting
A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations
NCT06124963Gastric Type Adenocarcinoma (GAS) With STK11 Mutation
DrugsWX390·Tislelizumab
Shanghai Jiatan Pharmatech Co., Ltd
Phase 2
20
Shanghai
2023-08-25
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589Asthma
DrugTezepelumab
AstraZeneca
Phase 3
231
Beijing, Changchun, Hohhot, Lanzhou, Nanjing, Shanghai, Shenyang, Shenzhen
2023-08-24
Active, closed
Cadonilimab (AK104) Plus Lenvatinib in Previously Immunotherapy-Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma
NCT06035224Clear Cell Renal Cell Carcinoma
RenJi Hospital
Phase 2
28
Shanghai
2023-08-23
Recruiting
Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer
NCT06039631Larynx Cancer, Hypopharyngeal Cancer
Fudan University
Phase 2
82
Shanghai
2023-08-22
Active, closed
Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNฮฑ Combination Therapy in Chronic HBV Patients
NCT05970289Chronic Hepatitis B Virus Infection
Brii Biosciences Limited
Phase 2
86
Beijing, Chongqing, Guangzhou, Hong Kong, Changchun, Shanghai, Kaohsiung, Taipei
2023-08-22
Recruiting
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)
NCT06975618PIK3CA-Related Overgrowth Spectrum (PROS), PIK3CA-related Vascular Malformations (PRVM)
DrugCYH33
Haihe Biopharma Co., Ltd.
Phase 1/2
141
Beijing, Fuzhou, Guangzhou, Zhengzhou, Changsha, Shanghai, Chengdu
2023-08-22
Recruiting
Maximal Tumor Eradication for Oligometastatic Prostate Cancer
NCT06972511Oligometastatic Prostate Cancer
RenJi Hospital
Phase 2/3
120
Shanghai
2023-08-20
Recruiting
An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus
NCT06010472Systemic Lupus Erythematosus (SLE)
Changhai Hospital
Phase EARLY_PHASE1
36
Shanghai
2023-08-20
Recruiting
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
NCT05999149TNBC - Triple-Negative Breast Cancer
Fudan University
Phase 3
424
Shanghai
2023-08-20
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
Daiichi Sankyo
Phase 1/2
590
Beijing, Jinan, Neijiang, Shanghai
2023-08-18
Recruiting
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
NCT05785741Advanced Solid Tumor
DrugsOsimertinib·Trastuzumab·Capecitabine
DualityBio Inc.
Phase 1/2
1,000
Zhengzhou, Changsha, Nanjing, Wuxi, Changchun, Shenyang, Shanghai, Chengdu
2023-08-17
Active, closed
AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
NCT05840016Advanced Squamous Non Small Cell Lung Cancer
Akeso
Phase 3
532
Shanghai
2023-08-17
Recruiting
CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
NCT06136364T-lymphoblastic Lymphoma, T-ALL
DrugCar-T
Hebei Senlang Biotechnology Inc., Ltd.
Phase 1
9
Shanghai
2023-08-15
Recruiting
A Multi-center Clinical Longitudinal Study of Neuropathic Pain by Collecting Data
NCT06290024Pain
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Observational
2,000
Shanghai
2023-08-15
Active, closed
Clinical Study of Allogeneic Fat Decellularized Active Protein in the Treatment of Pulmonary Fibrosis
NCT05883293Pulmonary Fibrosis
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase EARLY_PHASE1
7
Shanghai
2023-08-14
Recruiting
Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis
NCT05905172Liver Fibrosis
DrugHydronidone
Beijing Continent Pharmaceutical Co, Ltd.
Phase 3
248
Beijing, Shanghai, Bengbu, Changsha, Chongqing, Guizhou, Hangzhou, Henan
2023-08-12
Recruiting
Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent ฮฒ-thalassemia
NCT05776173ฮฒ-thalassemia Major
Shanghai BDgene Co., Ltd.
Not applicable
10
Shanghai
2023-08-10
Active, closed
SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI
NCT06020066Brain Metastases, Non-small Cell Lung Cancer
Fudan University
Phase 2
202
Shanghai
2023-08-10
Active, closed
ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma
NCT05479708Pancreatic Cancer Resectable
BAIYONG SHEN
Observational
150
Shanghai
2023-08-09
Active, closed
CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)
NCT05896137Primary Sclerosing Cholangitis
DrugCS0159
Cascade Pharmaceuticals, Inc
Phase 2
50
Hefei, Beijing, Wuhan, Changsha, Changchun, Jinan, Shanghai, Hangzhou
2023-08-07
Active, closed
S.T.O.P.ยฎ Technology Contact Lenses Versus Dual-focus Contact Lenses for Slowing Down Myopia Progression in Children
NCT05243836Myopia
nthalmic Pty Ltd
Not applicable
441
Wenzhou, Tianjin, Shanghai
2023-08-04
Recruiting
Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
NCT05698147Central Nervous System Lymphoma
DrugsMethotrexate·Selinexor·Rituximab
Tong Chen, MD
Phase 1/2
30
Hefei, Beijing, Fuzhou, Zhengzhou, Shanghai
2023-08-03
Recruiting
Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05942001Advanced Prostate Cancer
DrugsEnzalutamide Soft·HRS-5041·Prednisone Acetate·Abiraterone acetate
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
100
Shanghai
2023-08-03
Recruiting
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
NCT05867420Advanced Solid Tumors
DrugsFruquintinib·Paclitaxel·Bevacizumab
AskGene Pharma, Inc.
Phase 1/2
594
Beijing, Shanghai
2023-08-02
Recruiting
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05924750Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
DrugBL-M11D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
130
Hefei, Beijing, Haerbin, Shenyang, Jinan, Shanghai, Chengdu, Tianjin
2023-08-02
Recruiting
Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer
NCT05954078High-risk Stage II Colorectal Cancer, Stage III Colorectal Cancer, Circulating Tumor DNA Methylation
Fudan University
Phase 3
340
Shanghai
2023-08-01
Recruiting
Novel Therapy Target in Metastatic Prostate Cancer
NCT05577689Prostate Neoplasms
Fudan University
Observational
100
Shanghai
2023-08-01
By invitation
Association of Sleep Quality and Mental Status With Early Recurrence and Prognosis of Colorectal Cancer
NCT06443996Colorectal Cancer, Sleep Quality, Mental Status Change
Ma Yanlei
Observational
500
Shanghai
2023-08-01
Active, closed
Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody
NCT05994001Biliary Tract Cancer, Candonilimab, Claudin 18.2
DrugsCardonilizumab·LM-302
Shanghai Zhongshan Hospital
Phase 1/2
78
Shanghai
2023-08-01
Recruiting
Implantation of iodine125-Seeds Combined With Chemotherapy in the Treatment of Metastatic Pancreatic Carcinoma
NCT05869474Metastatic Pancreatic Cancer
Changhai Hospital
Not applicable
206
Shanghai
2023-08-01
Recruiting
The Effectiveness of the Letrozole-induced Endometrial Preparation Protocol in Frozen-thawed Embryo Transfer (FET)
NCT06006091Letrozole, Infertility, Female
International Peace Maternity and Child Health Hospital
Not applicable
858
Shanghai
2023-08-01
Active, closed
The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens
NCT05886348Myopia
HOYA Lens Thailand LTD.
Not applicable
249
Beijing, Guangzhou, Shanghai, Shengyang, Tianjin
2023-07-31
Not yet open
VitaFlowยฎ Transcatheter Aortic Valve Replacement System Pre-market Trial Long Term Follow Up ๏ผˆVITAL๏ผ‰
NCT05977257Aortic Valve Disease, Aortic Valve Stenosis
Shanghai MicroPort CardioFlow Medtech Co., Ltd.
Observational
89
Beijing, Chengdu, Hangzhou, Shanghai
2023-07-30
Recruiting
Regional Lymph Node Irradiation for High-risk pN0 Breast Cancer
NCT05976412Breast Cancer
Ruijin Hospital
Not applicable
1,355
Shanghai
2023-07-28
Recruiting
A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
NCT05934331Malignant Neoplasms of Digestive Organs
DrugsTegafur, Gimeracil and Oteracil Potassium·LM-302·Apatinib·Nivolumab
LaNova Medicines Zhejiang Co., Ltd.
Phase 2
276
Shanghai
2023-07-27
Recruiting
Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
NCT06227117Breast Cancer
RemeGen Co., Ltd.
Phase 2
120
Changsha, Shanghai, Tianjin, Hangzhou
2023-07-27
Active, closed
A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing
NCT05924256Advanced Salivary Gland Carcinoma
DrugsLeuprolide·SHR-A1921·Trastuzumab Rezetecan
Fudan University
Phase 2
88
Shanghai
2023-07-26
Recruiting
Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer
NCT05949541Breast Cancer, Advanced Breast Cancer
DrugsDalpiciclib·Everolimus
Fudan University
Phase 2
265
Shanghai
2023-07-26
Recruiting
Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC
NCT07136285SCLC, Extensive Stage
DrugsOlvi-Vec·Platinum (cisplatin·Etoposide·Carboplatin
Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.
Phase 1/2
27
Hangzhou, Shanghai
2023-07-24
Active, closed
Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)
NCT05861102Ankylosing Spondylitis
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3
265
Shanghai
2023-07-20
Recruiting
A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study
NCT05954429Colorectal Cancer
Fudan University
Phase 2
50
Shanghai
2023-07-20
Recruiting
DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC
NCT06354231Renal Insufficiency, Upper Urinary Tract Urothelial Carcinoma, Solitary Kidney
Fudan University
Phase 2
20
Shanghai
2023-07-20
Active, closed
A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT05880706Non-small Cell Lung Cancer
DrugsIza-bren·Osimertinib
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
198
Shanghai
2023-07-19
Active, closed
A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy
NCT06968585HER2-positive Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
365
Shanghai
2023-07-18
Active, closed
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
NCT05904379Advanced Non-small-cell Lung Cancer
DrugsCadonilimab·Pemetrexed·Carboplatin·Paclitaxel
Akeso
Phase 1/2
233
Hangzhou, Shanghai
2023-07-13
Recruiting
IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
NCT05994131NSCLC
DrugsIN10018·Furmonertinib
InxMed (Shanghai) Co., Ltd.
Phase 1/2
110
Shanghai
2023-07-13
Recruiting
A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
NCT05911217Pancreatic Cancer
DrugCT041 autologous CAR T-cell
CARsgen Therapeutics Co., Ltd.
Phase 1
20
Beijing, Zhengzhou, Wuhan, Changsha, Shanghai, Xian, Hangzhou
2023-07-11
Recruiting
A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
NCT05886920Advanced Solid Tumors With MAPK Pathway Mutations
DrugD3S-001
D3 Bio (Wuxi) Co., Ltd
Phase 1/2
67
Beijing, Guangzhou, Harbin, Wuhan, Shanghai, Chengdu, Hangzhou
2023-07-10
Active, closed
A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients
NCT05787613NSCLC Stage IV
Shanghai Henlius Biotech
Phase 2
132
Xuzhou, Shanghai
2023-07-10
Active, closed
Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer
NCT05969899Colorectal Cancer
DrugsFolfiri·Bevacizumab
Fudan University
Phase 2
50
Shanghai
2023-07-10
Recruiting
Efficacy of Electroacupuncture Versus Solifenacin Succinate for Female Overactive Bladder
NCT05798403Overactive Bladder
DrugSolifenacin Succinate
Yin Ping
Not applicable
204
Shanghai
2023-07-07
Recruiting
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
NCT05884255Advanced Gastroenteropancreatic Neuroendocrine Tumor
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
220
Shanghai, Tianjin
2023-07-06
Recruiting
Prizvalve Proโ„ข Transcatheter Aortic Valve Replacement Study
NCT05864456Aortic Valve Stenosis
Shanghai NewMed Medical Co., Ltd.
Not applicable
73
Shanghai
2023-07-05
Active, closed
Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors
NCT05914376Advanced Solid Tumors
Hangzhou Converd Co., Ltd.
Phase 1
24
Hangzhou, Shanghai
2023-07-05
Recruiting
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
NCT05727176Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
Taiho Oncology, Inc.
Phase 2
120
Guangzhou, Harbin, Nanjing, Changchun, Jinan, Shanghai, Chengdu, Hangzhou
2023-07-05
Recruiting
To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
NCT06045091Multiple Myeloma, Plasma Cell Leukemia
Hrain Biotechnology Co., Ltd.
Phase EARLY_PHASE1
18
Shanghai
2023-07-04
Recruiting
A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors
NCT05991583Advanced Malignant Tumors
SUNHO๏ผˆChina๏ผ‰BioPharmaceutical CO., Ltd.
Phase 1/2
25
Shanghai
2023-07-03
Not yet open
Atherectomy Followed With a Drug Coated Balloon in the Treatment of Long Femoropopliteal Lesions
NCT05868564Peripheral Arterial Disease
RenJi Hospital
Not applicable
100
Shanghai
2023-07-01
Recruiting
En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor.
NCT06120426Spinal Metastases, Spinal Tumor, Radiotherapy, Malignant Bone Tumor
Shanghai Changzheng Hospital
Observational
182
Shanghai
2023-07-01
Recruiting
Transvaginal NOSES Versus Conventional Laparoscopic Surgery for Right Hemicolectomy
NCT05495048Colon Cancer
Shanghai Minimally Invasive Surgery Center
Not applicable
356
Shanghai
2023-07-01
Recruiting
Non-invasive BCI and Application Verification for Depressed People
NCT06417437Depression, Major Depressive Disorder, Bipolar Depression
Shanghai Mental Health Center
Phase 4
400
Shanghai
2023-07-01
Recruiting
Safety and Preliminary Efficacy of iEVs Injection in Treating Lateral Epicondylitis of Humerus
NCT07111325Lateral Epicondylitis
DrugsIEV·PRP
Shanghai 6th People's Hospital
Phase 1/2
24
Shanghai
2023-07-01
Recruiting
Standardized Nutritional Management of Pediatric Patients With Solid Tumors
NCT06730204Tumor, Solid, Children, Nutritional Intervention
Children's Hospital of Fudan University
Not applicable
400
Shanghai
2023-07-01
Recruiting
Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy
NCT05925309Biliary Atresia, Cholangitis, Anti-Bacterial Agents
DrugsMeropenem·Ursodeoxycholic Acid·Methylprednisolone
Children's Hospital of Fudan University
Not applicable
356
Shanghai
2023-07-01
Recruiting
A Prospective Exploratory Clinical Study of Metronomic Capecitabine as Adjuvant Therapy in Locoregionally Advanced Hypopharyngeal Carcinoma
NCT05940441to Explore Whether the Adjuvant Therapy of Metronomic Capecitabine Could Improve the Disease-free Survival of Locoregionally Advanced Hypopharyngeal Carcinoma
DrugCapecitabine
Eye & ENT Hospital of Fudan University
Observational
74
Shanghai
2023-07-01
Not yet open
Anatomical Resection VS. Nonanatomical Resection for Colorectal Liver Metastases With Gene Mutation or Right-sidedness
NCT05881746Colorectal Carcinoma, Liver Metastases
Fudan University
Not applicable
176
Shanghai
2023-07-01
Recruiting
The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study
NCT05965115Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Shanghai Zhongshan Hospital
Observational
10,000
Shanghai
2023-07
Active, closed
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT05878769Chronic Obstructive Pulmonary Disease
DrugAstegolimab
Hoffmann-La Roche
Phase 3
2,000
Hefei, Beijing, Zunyi, Wuhan, Xuzhou, Pingxiang, Shanghai, Zigong
2023-06-28
Active, closed
Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients
NCT05751187Non-squamous NSCLC
DrugsDexamethasone·Pemetrexed·Cisplatin·Carboplatin
Shanghai Chest Hospital
Phase 2
54
Shanghai
2023-06-27
Active, closed
A Clinical Study Evaluating the Safety and Efficacy of SKG0201 Injection in Patients With Spinal Muscular Atrophy Type 1
NCT06191354Spinal Muscular Atrophy 1
Kun Sun
Not applicable
12
Chengdu, Shanghai
2023-06-25
Recruiting
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
NCT05803018Gynecological Malignant Tumor, Solid Tumor
DrugIza-bren
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
38
Shanghai
2023-06-25
Recruiting
Postoperative Effects of Different Enterostomy Approaches
NCT05853094Colorectal Cancer, Colorectal Neoplasms Malignant, Intestinal Neoplasms, Malignant
Fudan University
Not applicable
300
Shanghai
2023-06-23
Recruiting
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
NCT05427370Coronary Artery Disease, Heart Failure Systolic
Sunnybrook Health Sciences Centre
Not applicable
754
Jilin City, Shanghai
2023-06-22
Recruiting
Chemokine and Co-stimulatory Molecule-modified Mesenchymal Stem Cells for the Treatment of Advanced Colorectal Cancer
NCT06446050Advanced Colorectal Cancer
Shanghai East Hospital
Phase EARLY_PHASE1
30
Shanghai
2023-06-21
Recruiting
A Study of FZ-AD004 in Patients With Advanced Solid Tumors
NCT05914545Advanced and Metastatic Solid Tumor
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 1
121
Hangzhou, Shanghai, Xuzhou
2023-06-21
Recruiting
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
NCT05789082Non-Small Cell Lung Cancer
DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin
Hoffmann-La Roche
Phase 1/2
320
Changsha, Harbin, Shanghai
2023-06-20
Active, closed
FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
NCT05913037Neurofibromatosis 1, Plexiform Neurofibroma, NF1
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 3
167
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Wuhan, Shenyang, Shanghai, Chengdu
2023-06-20
Rows per page Showing 2901–3000 of 3827
Previous 28 29 30 31 32 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai?page=30

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,827 of those studies with a site in Shanghai.

How many clinical trials are recruiting in Shanghai?

2,393 of the 3,827 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 737 have not yet opened recruitment, 588 are active but closed to new participants, and 109 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.